Knight Therapeutics Inc. (TSX:GUD)
Canada flag Canada · Delayed Price · Currency is CAD
9.48
0.00 (0.00%)
Jun 15, 2026, 4:00 PM EST

Knight Therapeutics Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Knight Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.83. The average 1-year stock price forecast is 3.69% higher than the current stock price, while the lowest is $9.00 (-5.06%) and the highest is $12.00 (+26.58%).

Price Target: $9.83 (+3.69%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$9.00$9.83$9.50$12.00
Change-5.06%+3.69%+0.21%+26.58%
* Price targets were last updated on May 8, 2026.

Analyst Ratings

The average analyst rating for Knight Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingAug '25Nov '25Dec '25Feb '26Mar '26May '26
Strong Buy332224
Buy333333
Hold111110
Sell000000
Strong Sell000000
Total776667

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Canaccord Genuity
Canaccord Genuity
Buy
Initiates
$9.50
BuyInitiates$9.50+0.21%May 8, 2026
Stifel Nicolaus
Stifel Nicolaus
Buy
Maintains
$7.45
BuyMaintains$7.45-21.41%May 8, 2026
RBC Capital
RBC Capital
Buy
Maintains
$8.50$9.50
BuyMaintains$8.50$9.50+0.21%May 8, 2026
Bloom Burton
Bloom Burton
Buy
Maintains
$11.00$12.00
BuyMaintains$11.00$12.00+26.58%May 8, 2026

Financial Forecast

Revenue This Year
520.56M
from 450.09M
Increased by 15.66%
Revenue Next Year
527.66M
from 520.56M
Increased by 1.36%
EPS This Year
0.22
from 0.02
Increased by 844.21%
EPS Next Year
0.26
from 0.22
Increased by 18.18%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
243.48M293.56M328.20M371.30M450.09M520.56M
Revenue Growth
22.03%20.57%11.80%13.13%21.22%15.66%
Gross Profit
115.41M138.06M152.65M174.41M200.23M244.14M
Gross Margin
47.40%47.03%46.51%46.97%44.49%46.90%
Operating Income
-12.83M-17.06M6.37M7.40M-2.35M72.61M
Net Income
15.68M-29.89M-16.84M4.33M-5.37M18.61M
EPS
----0.020.22
EPS Growth
-----48.11%844.21%
Forward PE
82.43-79.24157.06201.6743.09
Free Cash Flow
-165.58M2.88M27.09M-9.70M20.39M41.20M
No. Analysts
-----7
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CAD.

Revenue Forecast

Revenue202620272028
High525.6M
Avg520.6M
Low514.2M

Revenue Growth

Revenue Growth202620272028
High
16.8%
Avg
15.7%
Low
14.2%

EPS Forecast

EPS202620272028
High0.22
Avg0.22
Low0.22

EPS Growth

EPS Growth202620272028
High
844.2%
Avg
844.2%
Low
844.2%